Akero

Akero is a pioneering clinical-stage biopharmaceutical software innovator of innovative therapies for severe metabolic diseases, most notably metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). Founded in January 2017 by Jonathan Young and Timothy Rolph, the company has rapidly established itself among the leaders in the metabolic disease therapeutics landscape, leveraging scientific rigor and translational medicine to address a major unmet medical need. With a mission centered on delivering transformational treatments for conditions that have limited or no effective existing options, Akero’s portfolio is anchored by its flagship compound, efruxifermin (EFX), an engineered analog of fibroblast growth factor 21 (FGF21). Efruxifermin (EFX), licensed from Amgen, is at the heart of Akero's R&D strategy and commercialization ambition. EFX is specifically designed to treat MASH, a severe progressive liver condition driven by metabolic dysfunction, fibrosis, and chronic inflammation. The disease remains one of the most significant unmet needs in metabolic medicine, with limited approved treatment options and a global patient population expected to rise in the coming years. Akero's scientific approach focuses on restoring systemic metabolic balance rather than merely addressing symptomatology, aiming for disease modification that can change long-term health trajectories for affected patients. The company’s growth and market visibility have been underscored by a series of substantial funding rounds and a successful IPO. As of mid-2025, Akero’s market capitalization stands near $1.7 billion, supported by strong institutional backing and a robust cash reserve exceeding $700 million, which sustains its R&D efforts and clinical programs. The company’s capital efficiency and financial stability align with the industry’s best practices for early-to-mid-stage biotech firms, though Akero has not yet generated commercial revenues as is typical for this stage of drug development. Clinical data positions EFX as one of the front-runners in the MASH/NASH therapeutic class. In multiple Phase 2 studies, including the prominent HARMONY trial, EFX demonstrated its potential to resolve MASH and reverse varying degrees of liver fibrosis—even advancing some patients with cirrhosis to lower fibrosis stages, which is a critical milestone for liver disease therapies. Beyond fibrosis, EFX has shown consistent improvement in key metabolic parameters such as insulin sensitivity and lipid profiles, suggesting additional long-term cardiometabolic benefits. The pipeline’s continued advancement hinges on Phase 3 SYNCHRONY program results, which, if positive, could set a new standard in MASH care and unlock a multi-billion-dollar market. Akero's business model centers on internal R&D execution and organic product expansion, rather than via acquisition. The company continues to build its scientific team and expand its clinical and regulatory capabilities to shepherd EFX through pivotal studies and toward commercial launch. Akero’s management emphasizes a culture of integrity, scientific curiosity, and a commitment to patient-centered innovation. This is reflected in its engagement with clinical trial participants, medical professionals, and the wider research community, as well as its transparency through frequent scientific publications and conference presentations.